Last reviewed · How we verify
NCT06624826
Visual Performance of an Extended Depth of Focus IOL in an Emmetropic or Monovision Modality
NA trial testing Emmetropic modality in Cataract in 60 participants. Currently enrolling.
1 October 2025
Quick facts
| Lead sponsor | Prim. Prof. Dr. Oliver Findl, MBA |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 1 October 2024 |
| Primary completion | 1 October 2025 |
| Estimated completion | 30 September 2026 |
| Sites | 1 location across Austria |
Drugs / interventions tested
- Emmetropic modality
- Monovision modality
Conditions studied
- Cataract — all drugs for Cataract →
Sponsor
Prim. Prof. Dr. Oliver Findl, MBA
Who can join
Adults 21 to 105, any sex, with Cataract. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Comparison of the visual performance of a refractive extended depth of focus intraocular lens in an emmetropic or monovision modality
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06624826
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cataract
Currently open trials in the same condition.
- NCT07301385 — Evaluation of Head-Mounted Spatial Computing and Three-Dimensional (3D) Visualization in Ocular Microsurgery: A Safety a · NA · recruiting
- NCT07462000 — Aqueous Humor and Ocular Tissue Analysis in Glaucoma and Cataract · NA · recruiting
- NCT06891092 — Vivinex Impress XY1-EM vs RayOne EMV · NA · recruiting
- NCT07218796 — Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compar · Phase 3 · recruiting
- NCT07218783 — Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compar · Phase 3 · recruiting
Other Prim. Prof. Dr. Oliver Findl, MBA trials
Trials by the same sponsor.
- NCT07425626 — Brillouin Scanning in Cataractous Eyes · active not recruiting
- NCT06459284 — Instrument Tissue Interaction at the Grasp Site During Membrane Peeling of Epiretinal Membranes · completed
- NCT06948851 — New Postoperative Intraretinal Cystoid Changes After Vitrectomy With Membrane Peeling Due to Epiretinal Membranes · active not recruiting
- NCT07436247 — Pseudophakic Eyes With Presbyopia-correcting IOLs: OCT Biometry and Pyramid Aberrometry · recruiting
- NCT06830070 — Subjective Pain Scoring for Subtenonal Anesthesia During Vitrectomy · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06624826 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Prim. Prof. Dr. Oliver Findl, MBA
- Last refreshed: 3 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06624826.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing